Akcea Therapeutics, Inc. (AKCA) financial statements (2020 and earlier)

Company profile

Business Address 22 BOSTON WHARF RD
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:464253260
Cash and cash equivalents3078658
Short-term investments157166202
Other undisclosed cash, cash equivalents, and short-term investments0(0) 
Receivables355
Inventory, net of allowances, customer advances and progress billings9  
Inventory9  
Contract with customer, asset10 
Other current assets11101
Other undisclosed current assets(0)0 
Total current assets:497267267
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment560
Intangible assets, net (including goodwill)83891
Intangible assets, net (excluding goodwill)83891
Other noncurrent assets331
Total noncurrent assets:102982
TOTAL ASSETS:599365269
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities373514
Accounts payable10122
Accrued liabilities14158
Employee-related liabilities1394
Deferred revenue2
Due to related parties 1914
Deferred revenue and credits51
Contract with customer, liability25
Other liabilities312
Total current liabilities:428181
Noncurrent Liabilities
Long-term debt and lease obligation14  
Operating lease, liability14
Liabilities, other than long-term debt 88
Deferred revenue and credits8
Contract with customer, liability3
Deferred rent credit 4
Total noncurrent liabilities:1488
Total liabilities:568989
Stockholders' equity
Stockholders' equity attributable to parent543277180
Common stock000
Additional paid in capital1,024799464
Accumulated other comprehensive income (loss)0(0)(0)
Accumulated deficit(481)(522)(284)
Total stockholders' equity:543277180
TOTAL LIABILITIES AND EQUITY:599365269

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Revenues4896555
Cost of revenue
(Cost of Goods and Services Sold)
 (3) 
Gross profit:4896255
Operating expenses(475)(296)(164)
Other undisclosed operating income243 
Operating income (loss):38(231)(109)
Nonoperating income552
Investment income, nonoperating662
Interest and debt expense  (2)
Income (loss) from continuing operations before income taxes:43(225)(108)
Income tax expense(2)(0)(1)
Net income (loss) attributable to parent:41(226)(110)
Preferred stock dividends and other adjustments  (20)
Other undisclosed net loss available to common stockholders, basic(13)(8) 
Net income (loss) available to common stockholders, diluted:27(234)(130)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net income (loss):41(226)(110)
Comprehensive income (loss):41(226)(110)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)
Comprehensive income (loss), net of tax, attributable to parent:41(226)(110)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: